3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
89
Phase 3
31
Phase 1
17
Phase 1/2
14
Phase 2/3
3
Phase NA
2
Phase 4
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Pancreatic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Lymphoma, T-Cell, Peripheral
2
Lymphoma, Extranodal NK-T-Cell
2
Thoracic Neoplasms
1
Squamous Non-small-cell Lung Cancer
1
Oligospermia
1
Non-small Cell Lung Cancer Metastatic
1
Neoplasms
1
Neoplasm Metastasis
1
Nasopharyngeal Neoplasms
1
Lymphohistiocytosis, Hemophagocytic
1
Lung Neoplasms
1
Lung Diseases
1
Fibrosis
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Biliary Tract Neoplasms
1
Adenocarcinoma Pancreas
1
Adenocarcinoma
1
Interventions
Propofol
6
Carboplatin
5
Sevoflurane
4
Saline Solution
3
Paclitaxel
3
Nivolumab
3
Erlotinib Hydrochloride
3
Acetaminophen
3
Pemetrexed
2
Midazolam
2
Lidocaine
2
Isoflurane
2
Docetaxel
2
Desflurane
2
Cryotherapy
2
Bupivacaine
2
Bronchoscopy
2
Anesthesia, Inhalation
2
trametinib
1
sotorasib
1
pegfilgrastim
1
icotinib
1
endostar protein
1
durvalumab
1
dabrafenib
1
capmatinib
1
camrelizumab
1
beta Carotene
1
atezolizumab
1
alectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Lung Neoplasms
×
Gemcitabine
×
Clear all
NCT05583188
2024-07-19
VIGOR
Galvanize Therapeutics, Inc.
Phase 4
Terminated
5 enrolled